Jasper Therapeutics (JSPR) Non Operating Income (2023 - 2025)

Jasper Therapeutics has reported Non Operating Income for 3 years, with the latest figure at $6.7 million in Q4 2025.

• On a quarterly basis, Non Operating Income rose 598.96% year-over-year to $6.7 million in Q4 2025; TTM through Dec 2025 was $8.1 million, a 62.62% increase from a year earlier, with the FY2025 full-year figure at $8.1 million, up 62.62% from the prior year.
• Non Operating Income was $6.7 million for Q4 2025 at Jasper Therapeutics, up from $430000.0 in the prior quarter.
• The five-year high for Non Operating Income was $6.7 million in Q4 2025, with the low at -$313000.0 in Q1 2023.
• Average Non Operating Income over 3 years is $1.5 million, with a median of $1.2 million recorded in 2023.
• The largest YoY upside for Non Operating Income was 598.96% in 2025 against a maximum downside of 74.96% in 2025.
• Over 3 years, Non Operating Income stood at $1.1 million in 2023, then decreased by 15.73% to $964000.0 in 2024, then surged by 598.96% to $6.7 million in 2025.
• The last three Non Operating Income figures came in at $6.7 million (Q4 2025), $430000.0 (Q3 2025), and $353000.0 (Q2 2025), per Business Quant data.